Literature DB >> 15953832

Applications and optimization of immunization procedures.

Michael K Schunk1, G Eileen Macallum.   

Abstract

Classical immunization protocols have produced an antibody-based humoral response that is very effective against susceptible infectious diseases. Immunization introduces an external substance to induce the host immune system to respond specifically. Typically an antigen is used, but DNA, or a primed, pre-existing leukocyte or antigen-presenting cell, can also be used. Immunization is currently being used or investigated for the prevention and treatment of infectious diseases, cancer, addictions, allergies, pregnancy, and autoimmune diseases. It is also being used to produce biologically active materials such as polyclonal and monoclonal antibodies, antivenins, and anti-toxins for treating a wide range of conditions. Animals have been integral to the development of immunization techniques, as producers of toxoids and antitoxins, as models (e.g., to validate materials and protocols used for immunization, to understand the impact of immunization itself on the immune system, and to help investigators devise methods for determining the efficacy of vaccines) and as beneficiaries themselves of vaccines and antitoxins. The choice of immunization protocols is complex, and results may be affected by many factors such as dose and concentration of antigen, choice of adjuvants, time between inoculation and response measurement, and method of detection. The immune system responses to an antigen are also complex and continue to develop with advancing age. Anatomical, physiological, and immune system differences between species influence responses to immunization, as do the purity and presentation of the antigens and adjuvants. When directly comparing results, animals should be sourced from the same supplier. This review highlights the many uses of immunization techniques and introduces important considerations for the choice of protocols and animal models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953832     DOI: 10.1093/ilar.46.3.241

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  16 in total

1.  Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.

Authors:  Amanda Trent; Bret D Ulery; Matthew J Black; John C Barrett; Simon Liang; Yulia Kostenko; Natalie A David; Matthew V Tirrell
Journal:  AAPS J       Date:  2014-12-20       Impact factor: 4.009

2.  Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.

Authors:  Elaheh Gheybi; Jafar Amani; Ali Hatef Salmanian; Farhad Mashayekhi; Samaneh Khodi
Journal:  Tumour Biol       Date:  2014-08-16

3.  Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Hai Yu; Roberto Duchi; Andrea Perota; Sophie Conchon; Shirley Bachar Abramovitch; Jean-Paul Soulillou; Cesare Galli; Xi Chen; Vered Padler-Karavani
Journal:  ACS Nano       Date:  2019-03-11       Impact factor: 15.881

4.  Systemic cytokine and chemokine responses in immunized mice challenged with staphylococcal enterotoxin B.

Authors:  Laura C Hudson Reichenberg; Renu Garg; Raymond Fernalld; Kenneth L Bost; Kenneth J Piller
Journal:  Toxicon       Date:  2017-05-03       Impact factor: 3.033

Review 5.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Michael R Turner; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-01-11       Impact factor: 3.534

6.  The importance of animal models in tuberculosis vaccine development.

Authors:  Armando Acosta; Mohd Nor Norazmi; Rogelio Hernandez-Pando; Nadine Alvarez; Reinier Borrero; Juan F Infante; Maria E Sarmiento
Journal:  Malays J Med Sci       Date:  2011-10

Review 7.  A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.

Authors:  Kavi Ratanabanangkoon
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

8.  Passive immunization by recombinant ferric enterobactin protein (FepA) from Escherichia coli O157.

Authors:  Seyed Mehdi Larrie-Bagha; Iraj Rasooli; Seyed Latif Mousavi-Gargari; Zohreh Rasooli; Shahram Nazarian
Journal:  Iran J Microbiol       Date:  2013-06

9.  Comparison of simple and rapid extracting methods of free-tags Mycobacterium tuberculosis protein 64 Recombinant Protein from polyacrylamide gel: Electroelution and the optimized passive elution.

Authors:  Sri Agung Fitri Kusuma; Ida Parwati; Toto Subroto; Yaya Rukayadi; Muhammad Fadhlillah; Asep Rizaludin
Journal:  J Adv Pharm Technol Res       Date:  2021-04-27

10.  Identification and Characterization of the Amphioxus Lck and Its Associated Tyrosine Phosphorylation-Dependent Inhibitory LRR Receptor.

Authors:  Jiatao Zhou; Zhihui Xiao; Yanli Zhan; Xuemei Qu; Sisi Mou; Chong Deng; Tianxiang Zhang; Xin Lan; Shengfeng Huang; Yingqiu Li
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.